Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 West 4th Ave, Vancouver, Canada

BstnGeorge Jan. 10 at 1:56 AM

$ABCL $50 stock or $10B market cap?

0 · Reply

UncleTomFlorida Jan. 10 at 1:40 AM

$ABCL

0 · Reply

UncleTomFlorida Jan. 10 at 1:39 AM

$ABCL Take a look at $ABCL’s new building on Google maps. Very impressive.

0 · Reply

OnChainAce Jan. 10 at 1:21 AM

$ABCL What a week we had! I feel like this is just the start. S/O to everyone who doubled and tripled down under $4. 2026 is the year of biotech and Abcellera will lead the way. Don't let Ed shake you out of generational wealth

0 · Reply

Ed_Ng Jan. 10 at 12:37 AM

$ABCL the 6 years chart says its own.

1 · Reply

ITF Jan. 9 at 11:31 PM

$ABCL ED_nothingburger, maybe once try to convince why we should be negative and short the stock,why?

0 · Reply

Ed_Ng Jan. 9 at 10:35 PM

$ABCL how about you? I thought you blocked me ;-). You guys are emotional trading and rely on ChatGPT. lol.

0 · Reply

Stocktradesmoon Jan. 9 at 9:54 PM

$ABCL

0 · Reply

estatebuyersmia Jan. 9 at 9:47 PM

$ABCL I FINALLY BLOCKED ED....

0 · Reply

PLTRLONGDONG Jan. 9 at 8:19 PM

$ABCL Current rev- 35.3M If 575($10B Addressable Market)and 635 ($2B Addressable Market) drugs are successful we are looking at potentially $12 Billion annually. Say 50% of the market is claimed and annual revenue is $6B. With no dilution that is $300 a share at a 15x multiple. Most biotechs trade at 30x. Hold strong and buy if you have faith in this company and leadership. This is a generational wealth builder.

1 · Reply

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 4 weeks ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 1:37 PM EST - 4 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 22, 2025, 12:23 AM EST - 6 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 10, 2025, 9:00 AM EST - 2 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 7, 2025, 7:16 PM EST - 2 months ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 2 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 6, 2025, 7:35 AM EDT - 3 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

Sep 29, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 4 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 4 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 7:48 PM EDT - 5 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 5 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 8 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 8 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 8 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 8 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 10:33 PM EDT - 8 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 8 months ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 9 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 10 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 11:26 PM EST - 11 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 11 months ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 1 year ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

BstnGeorge Jan. 10 at 1:56 AM

$ABCL $50 stock or $10B market cap?

0 · Reply

UncleTomFlorida Jan. 10 at 1:40 AM

$ABCL

0 · Reply

UncleTomFlorida Jan. 10 at 1:39 AM

$ABCL Take a look at $ABCL’s new building on Google maps. Very impressive.

0 · Reply

OnChainAce Jan. 10 at 1:21 AM

0 · Reply

Ed_Ng Jan. 10 at 12:37 AM

$ABCL the 6 years chart says its own.

1 · Reply

ITF Jan. 9 at 11:31 PM

$ABCL ED_nothingburger, maybe once try to convince why we should be negative and short the stock,why?

0 · Reply

Ed_Ng Jan. 9 at 10:35 PM

$ABCL how about you? I thought you blocked me ;-). You guys are emotional trading and rely on ChatGPT. lol.

0 · Reply

Stocktradesmoon Jan. 9 at 9:54 PM

$ABCL

0 · Reply

estatebuyersmia Jan. 9 at 9:47 PM

$ABCL I FINALLY BLOCKED ED....

0 · Reply

PLTRLONGDONG Jan. 9 at 8:19 PM

1 · Reply

JennyRowes Jan. 9 at 8:16 PM

$ABCL wow… huge week!

0 · Reply

Samb2344 Jan. 9 at 7:04 PM

$ABCL agree we’ve already seen $5 area what’s a dollar more

0 · Reply

tkstockpicker Jan. 9 at 6:54 PM

$ABCL trimmed for 25% gain on those

1 · Reply

Ed_Ng Jan. 9 at 5:59 PM

$ABCL we can't trust they guy who sold at 4 last year. What you are saying now is just a POS. You are just a swing trader like most of us

1 · Reply

pointnopoint Jan. 9 at 5:54 PM

$ABCL This looks similar to the start of the run in May-June 2025

1 · Reply

theroller Jan. 9 at 5:12 PM

$ABCL will take off 🚀

0 · Reply

MartinMercados Jan. 9 at 4:49 PM

$ABCL Things are looking good if we end up in positive territory; the chances of seeing $5.50 next week are increasing.

0 · Reply

estatebuyersmia Jan. 9 at 4:42 PM

$ABCL

0 · Reply

Ed_Ng Jan. 9 at 4:02 PM

$ABCL @estatebuyersmia and this. Do more research. Don't be so stupid!

1 · Reply

Ed_Ng Jan. 9 at 4:01 PM

$ABCL @estatebuyersmia check it out

0 · Reply

Ed_Ng Jan. 9 at 3:57 PM

$ABCL why? I took my 50% profit from short already. It's purely pump and dump with low volume. I will add to my short position soon. This POS is my trade heaven and I made shitloads of money out of it during the last 5 years. Keep praying on a green day 😂

1 · Reply

POETMOONSHOT Jan. 9 at 3:57 PM

$ABCL what is the target here??

1 · Reply

Market Cap	1.23B
Revenue (ttm)	28.83M
Net Income (ttm)	-162.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-564.90%
Debt to Equity Ratio	0.00

Volume	6,460,800
Avg Vol	4,298,132
Day's Range	N/A - N/A
Shares Out	299.34M
Stochastic %K	88%
Beta	0.73
Analysts	Strong Sell
Price Target	$9.00